| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.35 | 7e-27 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.31 | 7e-22 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-13 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.23 | 6e-12 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.24 | 7e-12 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.43 | 1e-09 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.2 | 9e-09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-08 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |